1.
Proc West Pharmacol Soc
; 44: 15-7, 2001.
Artículo
en Inglés
| MEDLINE
| ID: mdl-11793965
Asunto(s)
Inflamación/patología , Interleucina-1/fisiología , Dolor/patología , Prostaglandina-Endoperóxido Sintasas/fisiología , Factor de Necrosis Tumoral alfa/fisiología , Animales , Antiinflamatorios no Esteroideos/farmacología , Anticuerpos Bloqueadores/farmacología , Celecoxib , Inhibidores de la Ciclooxigenasa/farmacología , Diclofenaco/farmacología , Femenino , Formaldehído , Inflamación/inducido químicamente , Interleucina-1/antagonistas & inhibidores , Masculino , Dolor/inducido químicamente , Dimensión del Dolor/efectos de los fármacos , Pirazoles , Ratas , Ratas Wistar , Sulfonamidas/farmacología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
2.
Eur J Pharmacol
; 340(2-3): 177-80, 1997 Dec 11.
Artículo
en Inglés
| MEDLINE
| ID: mdl-9537812
RESUMEN
The effect of inhibition of nitric oxide synthesis and guanylate cyclase on the peripheral antinociceptive effect of morphine was assessed by using the formalin test in the rat. Saline, N(G)-monomethyl-L-arginine, a nitric oxide synthesis inhibitor (50 microg) and methylene blue, a guanylate cyclase inhibitor (500 microg), did not exhibit any antinociceptive activity. However, morphine (10 microg) produced a significant antinociceptive effect in phases 2a and 2b, which was reduced by pretreatment with either N(G)-monomethyl-L-arginine or methylene blue. These results suggest that the local administration of morphine induces antinociception by the activation of the L-arginine-nitric oxide-cGMP pathway.